Table 3

Variables at baseline, pre-propensity and post-propensity score matching for patients with ≥1 year of follow-up from pooled LTE and Toronto Lupus Cohort datasets

Variable	Pre-propensity score matching (n=1541)			Post-propensity score matching (n=646)
	Mean		% Bias	Mean		% Bias
	Belimumab	Standard therapy	% Bias	Belimumab	Standard therapy	% Bias
Age	38.782	36.735	16.2	38.108	37.416	5.4
Age squared	1634.0	1538.5	9.0	1611.1	1566.9	4.2
Female	0.942	0.885	20.4	0.926	0.913	4.5
Race
Black	0.075	0.150	−24.1	0.115	0.108	2.0
Asian/other	0.457	0.301	32.7	0.337	0.362	−5.2
SLE duration	6.737	6.358	5.5	7.061	6.803	3.6
Hypertension	0.400	0.383	3.3	0.412	0.402	1.9
Dyslipidaemia	0.128	0.471	−80.7	0.279	0.282	−0.7
Proteinuria	0.169	0.346	−41.3	0.245	0.263	−4.3
ACR criteria	5.971	5.674	21.6	5.901	5.892	0.7
Baseline SLEDAI	8.273	10.100	−39.8	9.105	9.046	1.4
Corticosteroid use	0.859	0.639	52.5	0.715	0.743	−6.3
Antimalarial use	0.669	0.593	15.8	0.656	0.628	5.8
Immunosuppressive use	0.472	0.372	20.4	0.399	0.409	−1.9
Baseline SDI=1	0.241	0.150	22.9	0.235	0.195	9.8
Baseline SDI≥2	0.177	0.103	21.3	0.133	0.139	−1.8

ACR, American College of Rheumatology; LTE, long-term extension; SDI, SLICC/ACR Damage Index; SLE, systemic lupus erythematosus;; SLEDAI, Systemic Lupus Erythematosus Disease Activity Index; SLICC, Systemic Lupus International Collaborating Clinics.